Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19].

Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, Gaddh M, Garcia D, Grosso MA, Kakkar AK, Mercuri MF, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob G.

Thromb Res. 2020 Mar 6. pii: S0049-3848(20)30069-4. doi: 10.1016/j.thromres.2020.02.022. [Epub ahead of print] No abstract available.

PMID:
32151398
2.

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation.

Fox KAA, Velentgas P, Camm AJ, Bassand JP, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Dabrowski E, Luo K, Gibbs L, Kakkar AK; GARFIELD-AF Investigators.

JAMA Netw Open. 2020 Feb 5;3(2):e200107. doi: 10.1001/jamanetworkopen.2020.0107.

3.

Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry.

Hacke W, Bassand JP, Virdone S, Camm AJ, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AG, van Eickels M, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Int J Stroke. 2019 Dec 17:1747493019891516. doi: 10.1177/1747493019891516. [Epub ahead of print]

PMID:
31847794
4.

New AI Prediction Model Using Serial PT-INR Measurements in AF Patients on VKAs: GARFIELD-AF.

Goto S, Goto S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J Cardiovasc Pharmacother. 2019 Dec 10. pii: pvz076. doi: 10.1093/ehjcvp/pvz076. [Epub ahead of print]

PMID:
31821482
5.

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events.

Atar D, Berge E, Le Heuzey JY, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand JP, Kakkar AK; GARFIELD-AF Investigators.

Europace. 2020 Feb 1;22(2):195-204. doi: 10.1093/europace/euz292.

6.

Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.

Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, Gaddh M, Garcia D, Grosso MA, Kakkar AK, Mercuri MF, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz JI, Zhang G, Büller HR, Raskob G.

Thromb Res. 2020 Jan;185:13-19. doi: 10.1016/j.thromres.2019.11.007. Epub 2019 Nov 9. Erratum in: Thromb Res. 2020 Mar 6;:.

PMID:
31733403
7.

GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study.

Dalgaard F, Pieper K, Verheugt F, Camm AJ, Fox KA, Kakkar AK, Pallisgaard JL, Rasmussen PV, Weert HV, Lindhardt TB, Torp-Pedersen C, Gislason GH, Ruwald MH, Harskamp RE.

BMJ Open. 2019 Nov 11;9(11):e033283. doi: 10.1136/bmjopen-2019-033283.

8.

The Thrombosis Research Institute, London.

Kakkar AK, Camm AJ, Fox KAA.

Eur Heart J. 2019 Jul 14;40(27):2184-2186. doi: 10.1093/eurheartj/ehz494. No abstract available.

PMID:
31505614
9.

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A.

J Clin Oncol. 2020 Feb 10;38(5):496-520. doi: 10.1200/JCO.19.01461. Epub 2019 Aug 5.

PMID:
31381464
10.

Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry.

Schellong SM, Goldhaber SZ, Weitz JI, Ageno W, Bounameaux H, Turpie AGG, Angchaisuksiri P, Haas S, Goto S, Zaghdoun A, Farjat A, Nielsen JD, Kayani G, Mantovani LG, Prandoni P, Kakkar AK.

Thromb Haemost. 2019 Oct;19(10):1675-1685. doi: 10.1055/s-0039-1693461. Epub 2019 Aug 1.

11.

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.

Verheugt FWA, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

Am J Med. 2019 Dec;132(12):1431-1440.e7. doi: 10.1016/j.amjmed.2019.06.008. Epub 2019 Jul 12.

PMID:
31306621
12.

Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.

Haas S, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Zaghdoun A, Farjat AE, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK.

J Thromb Haemost. 2019 Oct;17(10):1694-1706. doi: 10.1111/jth.14548. Epub 2019 Jul 23.

PMID:
31220403
13.

Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry.

Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Farjat AE, Zaghdoun A, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Darius H, Kakkar AK.

Thromb Haemost. 2019 Aug;119(8):1365-1372. doi: 10.1055/s-0039-1688828. Epub 2019 Jun 10.

PMID:
31183844
14.

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey JY, Haas S, Turpie AGG, Virdone S, Kakkar AK; RIVER Registry Investigators.

Thromb J. 2019 Apr 25;17:7. doi: 10.1186/s12959-019-0195-7. eCollection 2019.

15.

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators.

Gastroenterology. 2019 Sep;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056. Epub 2019 May 29.

PMID:
31152740
16.

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.

Haas S, Camm AJ, Bassand JP, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Am Heart J. 2019 Jul;213:35-46. doi: 10.1016/j.ahj.2019.03.013. Epub 2019 Apr 11.

17.

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.

Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

JAMA Cardiol. 2019 Jun 1;4(6):526-548. doi: 10.1001/jamacardio.2018.4729.

PMID:
31066873
18.

Methodological Characteristics of Clinical Trials: Impact of Mandatory Trial Registration.

Kakkar AK, Padhy BM, Sarangi SC, Gupta YK.

J Pharm Pharm Sci. 2019;22(1):131-141. doi: 10.18433/jpps30360.

19.

Posttrial Access to Medical Interventions: Intricacies, Challenges, and Solutions.

Singh H, Rao SV, Kakkar AK, Singh J, Manohar HD.

Int J Appl Basic Med Res. 2019 Jan-Mar;9(1):3-8. doi: 10.4103/ijabmr.IJABMR_218_18. Review.

20.

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators.

N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.

PMID:
30786186
21.

Ensuring access to 'access' antibiotics: an imminent consideration for sustainable antimicrobial stewardship in the developing world.

Kakkar AK, Shafiq N, Malhotra S.

Infect Dis (Lond). 2019 May;51(5):395-398. doi: 10.1080/23744235.2019.1574978. Epub 2019 Feb 19. No abstract available.

PMID:
30776933
22.

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.

Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD‐AF Investigators.

J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.

23.

Satisfaction With Statin Treatment Among Adult Coronary Artery Disease Patients: An Experience From a Resource-Constrained Setting.

Mulchandani R, Lyngdoh T, Chakraborty P, Kakkar AK.

Heart Lung Circ. 2019 Dec;28(12):1788-1794. doi: 10.1016/j.hlc.2018.10.024. Epub 2018 Dec 10.

PMID:
30704841
24.

Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.

Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Pieper KS, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators.

Thromb Haemost. 2019 Feb;119(2):319-327. doi: 10.1055/s-0038-1676611. Epub 2018 Dec 28.

PMID:
30593086
25.

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation.

Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK.

Circulation. 2019 Feb 5;139(6):787-798. doi: 10.1161/CIRCULATIONAHA.118.035012.

PMID:
30586740
26.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

Sawhney JP, Kothiwale VA, Bisne V, Durgaprasad R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawla K, Allu J, Pieper KS, John Camm A, Kakkar AK; GARFIELD-AF Investigators.

Indian Heart J. 2018 Nov - Dec;70(6):828-835. doi: 10.1016/j.ihj.2018.09.001. Epub 2018 Sep 12.

27.

Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan - Insights From GARFIELD-AF.

Koretsune Y, Etoh T, Katsuda Y, Suetsugu T, Kumeda K, Sakuma I, Eshima K, Shibuya M, Ando SI, Yokota N, Goto S, Pieper KS, Allu J, Kakkar AK; GARFIELD-AF Investigators.

Circ J. 2018 Dec 25;83(1):67-74. doi: 10.1253/circj.CJ-18-0655. Epub 2018 Dec 4.

28.

Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions.

Mulchandani R, Kakkar AK.

Int J Risk Saf Med. 2019;30(1):33-44. doi: 10.3233/JRS-180025. Review.

PMID:
30175985
29.

mHealth technologies in clinical trials: Opportunities and challenges.

Kakkar AK, Sarma P, Medhi B.

Indian J Pharmacol. 2018 May-Jun;50(3):105-107. doi: 10.4103/ijp.IJP_391_18. No abstract available.

30.

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.

Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Zwicker JI, Büller HR, Raskob GE.

Thromb Haemost. 2018 Aug;118(8):1439-1449. doi: 10.1055/s-0038-1667001. Epub 2018 Jul 30.

PMID:
30060256
31.

Old wines in new bottles: Repurposing opportunities for Parkinson's disease.

Kakkar AK, Singh H, Medhi B.

Eur J Pharmacol. 2018 Jul 5;830:115-127. doi: 10.1016/j.ejphar.2018.04.023. Epub 2018 Apr 22. Review.

PMID:
29689247
32.

Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, Bauersachs R, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Kakkar AK, van Bellen B, Pap AF, Homering M, Tamm M, Weitz JI.

Blood Adv. 2018 Apr 10;2(7):788-796. doi: 10.1182/bloodadvances.2018017160.

33.

Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.

Goyal A, Singh H, Sehgal VK, Jayanthi CR, Munshi R, Bairy KL, Kumar R, Kaushal S, Kakkar AK, Ambwani S, Goyal C, Mazumdar G, Adhikari A, Das N, Stephy DJ, Thangaraju P, Dhasmana DC, Rehman SU, Chakrabarti A, Bhandare B, Badyal DK, Kaur I, Chandrashekar K, Singh J, Dhamija P, Sarangi SC, Gupta YK.

Indian J Med Res. 2017 Oct;146(4):468-475. doi: 10.4103/ijmr.IJMR_1416_15.

34.

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, Fox KAA, Gao H, Goldhaber SZ, Goto S, Haas S, Kayani G, Pieper K, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

PLoS One. 2018 Jan 25;13(1):e0191592. doi: 10.1371/journal.pone.0191592. eCollection 2018.

35.

Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry.

Verheugt FWA, Gao H, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand JP, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J. 2018 Feb 7;39(6):464-473. doi: 10.1093/eurheartj/ehx730.

PMID:
29281086
36.

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

BMJ Open. 2017 Dec 21;7(12):e017157. doi: 10.1136/bmjopen-2017-017157.

37.

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators.

N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12.

38.

Statin related adverse effects and patient education: a study from resource limited settings.

Mulchandani R, Lyngdoh T, Chakraborty P, Kakkar AK.

Acta Cardiol. 2018 Aug;73(4):393-401. doi: 10.1080/00015385.2017.1406884. Epub 2017 Nov 27.

PMID:
29179650
39.

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.

Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators.

Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.

40.

Erratum.

Fox KAA, Gersh BJ, Traore S, John Camm A, Kayani G, Krogh A, Shweta S, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J Qual Care Clin Outcomes. 2017 Oct 1;3(4):328. doi: 10.1093/ehjqcco/qcx024. No abstract available.

PMID:
29044400
41.

Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Fox KAA, Accetta G, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Kayani G, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):27-35. doi: 10.1093/ehjqcco/qcx030.

PMID:
28950344
42.

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.

Khorana AA, Vadhan-Raj S, Kuderer NM, Wun T, Liebman H, Soff G, Belani C, O'Reilly EM, McBane R, Eikelboom J, Damaraju CV, Beyers K, Dietrich F, Kakkar AK, Riess H, Peixoto RD, Lyman GH.

Thromb Haemost. 2017 Nov 1;117(11):2135-2145. doi: 10.1160/TH17-03-0171. Epub 2017 Sep 21.

43.

Evolving quality standards for large-scale registries: the GARFIELD-AF experience.

Fox KAA, Gersh BJ, Traore S, John Camm A, Kayani G, Krogh A, Shweta S, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J Qual Care Clin Outcomes. 2017 Apr 1;3(2):114-122. doi: 10.1093/ehjqcco/qcw058. Review. Erratum in: Eur Heart J Qual Care Clin Outcomes. 2017 Oct 1;3(4):328.

PMID:
28927171
44.

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators.

N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.

45.

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators.

N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18.

46.

Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry.

Camm AJ, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber SZ, Haas S, Jansky P, Kayani G, Misselwitz F, Oh S, Oto A, Raatikainen P, Steffel J, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

BMJ Open. 2017 Mar 6;7(3):e014579. doi: 10.1136/bmjopen-2016-014579.

47.

Magnetic resonance fingerprinting based on realistic vasculature in mice.

Pouliot P, Gagnon L, Lam T, Avti PK, Bowen C, Desjardins M, Kakkar AK, Thorin E, Sakadzic S, Boas DA, Lesage F.

Neuroimage. 2017 Apr 1;149:436-445. doi: 10.1016/j.neuroimage.2016.12.060. Epub 2016 Dec 31.

48.

Effect of lamotrigine, levetiracetam & topiramate on neurobehavioural parameters & oxidative stress in comparison with valproate in rats.

Sarangi SC, Kakkar AK, Kumar R, Gupta YK.

Indian J Med Res. 2016 Jul;144(1):104-111. doi: 10.4103/0971-5916.193296.

49.

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.

Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

PLoS One. 2016 Oct 28;11(10):e0164076. doi: 10.1371/journal.pone.0164076. eCollection 2016.

50.

Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.

Weitz JI, Haas S, Ageno W, Angchaisuksiri P, Bounameaux H, Nielsen JD, Goldhaber SZ, Goto S, Kayani G, Mantovani L, Prandoni P, Schellong S, Turpie AG, Kakkar AK.

Thromb Haemost. 2016 Nov 30;116(6):1172-1179. Epub 2016 Sep 22.

PMID:
27656711

Supplemental Content

Loading ...
Support Center